Published: 2024-07-01 July 01, 2024 08:00 AM Eastern Daylight Time – Funding will advance development of Rejuvenate’s one-time gene therapy RJB-0402 for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy SAN DIEGO–(BUSINESS WIRE)–Rejuvenate Bio, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to complete IND-enabling activities...Read More